[go: up one dir, main page]

WO1998010786A3 - Composition pharmaceutique pour le traitement du syndrome x de reaven - Google Patents

Composition pharmaceutique pour le traitement du syndrome x de reaven Download PDF

Info

Publication number
WO1998010786A3
WO1998010786A3 PCT/IL1997/000301 IL9700301W WO9810786A3 WO 1998010786 A3 WO1998010786 A3 WO 1998010786A3 IL 9700301 W IL9700301 W IL 9700301W WO 9810786 A3 WO9810786 A3 WO 9810786A3
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
reaven
treatment
pharmaceutical composition
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL1997/000301
Other languages
English (en)
Other versions
WO1998010786A2 (fr
Inventor
Yarom Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11925096A external-priority patent/IL119250A/xx
Priority claimed from IL11940396A external-priority patent/IL119403A/en
Application filed by Individual filed Critical Individual
Priority to AU41339/97A priority Critical patent/AU4133997A/en
Publication of WO1998010786A2 publication Critical patent/WO1998010786A2/fr
Publication of WO1998010786A3 publication Critical patent/WO1998010786A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant, en tant que principe actif, un composé choisi parmi la somatostatine ou un de ses analogues, le diazoxyde ou un de ses analogues, le cyclothiazidéor ou un de ses analogues et la metformine, pour le traitement du syndrome X de Raeven (également appelé syndrome d'hyperinsulinémie ou 'quartet meurtrier').
PCT/IL1997/000301 1996-09-12 1997-09-10 Composition pharmaceutique pour le traitement du syndrome x de reaven Ceased WO1998010786A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU41339/97A AU4133997A (en) 1996-09-12 1997-09-10 Pharmaceutical composition for the treatment of syndrome x of reaven

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL11925096A IL119250A (en) 1996-09-12 1996-09-12 Pharmaceutical composition for the treatment of syndrome x of reaven
IL119250 1996-09-12
IL119403 1996-10-10
IL11940396A IL119403A (en) 1996-10-10 1996-10-10 Pharmaceutical composition for the treatment of syndrome x of reaven

Publications (2)

Publication Number Publication Date
WO1998010786A2 WO1998010786A2 (fr) 1998-03-19
WO1998010786A3 true WO1998010786A3 (fr) 1998-08-27

Family

ID=26323304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1997/000301 Ceased WO1998010786A2 (fr) 1996-09-12 1997-09-10 Composition pharmaceutique pour le traitement du syndrome x de reaven

Country Status (2)

Country Link
AU (1) AU4133997A (fr)
WO (1) WO1998010786A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058557B2 (en) 2014-11-14 2018-08-28 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10085998B2 (en) 2006-01-05 2018-10-02 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69816808T2 (de) * 1997-05-13 2004-04-15 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin agoniste zur reduzierung von körpergewicht
US7026289B2 (en) 1997-05-13 2006-04-11 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Method and compositions for treating hyperlipidemia and other conditions
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
AU8019898A (en) * 1997-05-13 1998-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
EP1291022A1 (fr) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Procédés d'utilisation du lanréotide, un analogue de la somatostatine
KR20010071071A (ko) * 1998-07-30 2001-07-28 다푸르 가브리에 성장억제 호르몬 유사체의 사용방법
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2002072602A2 (fr) * 2001-03-08 2002-09-19 The Administrators Of The Tulane Educational Fund Antagonistes de la somatostatine
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
CN104958270A (zh) 2004-08-25 2015-10-07 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2395987A1 (fr) * 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
WO2013130411A1 (fr) 2012-02-27 2013-09-06 Essentialis, Inc. Sels d'ouvreurs des canaux potassiques atp et leurs utilisations
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100153A (en) * 1977-05-11 1978-07-11 American Home Products Corporation (D-Trp5)-somatostatin and analogues thereof
US4159263A (en) * 1977-05-11 1979-06-26 American Home Products Corporation (D-Ala5)-somatostatin and analogues thereof
EP0374089A2 (fr) * 1988-11-11 1990-06-20 Sandoz Ag Utilisation de dérivés de la somatostatine comme agents protecteurs des poumons

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100153A (en) * 1977-05-11 1978-07-11 American Home Products Corporation (D-Trp5)-somatostatin and analogues thereof
US4159263A (en) * 1977-05-11 1979-06-26 American Home Products Corporation (D-Ala5)-somatostatin and analogues thereof
EP0374089A2 (fr) * 1988-11-11 1990-06-20 Sandoz Ag Utilisation de dérivés de la somatostatine comme agents protecteurs des poumons

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLUMING A.Z. ET AL: "Successful treatment of unstable angina in malignant carcinoid syndrome using the long acting somatostatin analogue SMS 201-995 (sandostatin)", THE AMERICAN JOURNAL OF MEDICINE, vol. 85, 1988, pages 872 - 874, XP002053036 *
BOYLE P.J. ET AL: "Octeotride reverses hyperinsulinaemia and prevents hypoglycemia induced by sulfonilurea overdoses", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 76, no. 3, 1993, pages 752 - 756, XP002053033 *
CARRETTA, R. ET AL: "Reduction of blood pressure in obese hyperinsulinaemic hypertensive patients during somatostatin infusion", JOURNAL OF HYPERTENSION SUPPLEMENT, vol. 7, 1989, pages s196 - s197, XP002053034 *
GUILLAUME G. ET AL: "Syndrome X et médecine générale", REVUE MEDICALE DE BRUXELLES, vol. 16, no. 2, 1995, XP002053039 *
KIRK, J.M.W. ET AL: "Somatostatin analogue in short term management of hyperinsulinism", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 63, no. 12, 1988, pages 14931494, XP002053035 *
PHILLIPS R.E. ET AL: "Effectiveness of SMS 201-995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia", LANCET THE, vol. 1, 1986, LONDON GB, pages 713 - 715, XP002053032 *
RAYNOR K ET AL: "Characterization of cloned somatostatin receptors SSTR4 and SSTR5", MOLECULAR PHARMACOLOGY, vol. 44, no. 2, August 1993 (1993-08-01), pages 385 - 392, XP000644418 *
RAYNOR K ET AL: "Cloned somatostatin receptors: identification of subtype-selective peptides and demostration of high affinity binding of linear peptides", MOLECULAR PHARMACOLOGY, vol. 43, no. 6, June 1993 (1993-06-01), pages 838 - 844, XP000676382 *
SIRTORI C.R. ET AL: "Re-evaluation of a biguanide, Metformin: mechanism of action and tolerability", PHARMACOLOGICAL RESEARCH, vol. 30, no. 3, 1994, pages 187 - 228, XP002053037 *
SMITH U.: "Clinical and therapeutical aspects of the insulin resistance syndrome", CARDIOVASCULAR RISK FACTORS, vol. 3, no. 1, 1993, pages 67 - 73, XP002053038 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10085998B2 (en) 2006-01-05 2018-10-02 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US11045478B2 (en) 2006-01-05 2021-06-29 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US11786536B2 (en) 2006-01-05 2023-10-17 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US10058557B2 (en) 2014-11-14 2018-08-28 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10456408B2 (en) 2014-11-14 2019-10-29 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US10874676B2 (en) 2014-11-14 2020-12-29 Essentials, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US12109216B2 (en) 2014-11-14 2024-10-08 Essentials, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US12178823B1 (en) 2014-11-14 2024-12-31 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US12343348B2 (en) 2014-11-14 2025-07-01 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

Also Published As

Publication number Publication date
AU4133997A (en) 1998-04-02
WO1998010786A2 (fr) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998010786A3 (fr) Composition pharmaceutique pour le traitement du syndrome x de reaven
CA2235318A1 (fr) Procede de lutte contre les myiases des cheptels bovins et ovins et compositions pour la mise en oeuvre de ce procede
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
CA2179648A1 (fr) Compositions herbicides sous forme d'une solution d'azote et d'ether de diphenyle et leur procede d'utilisation
WO1998045259A3 (fr) Compositions antivirales polyaromatiques
CA2370201A1 (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau
EP0889085A3 (fr) N,N',N'''-Tris(2,4-bis(1-hydrocarbyloxy-2,2,6,6,-tetramethylpiperidin-4-yl)alkylamino)-s-triazin-6-yl)-3,3'-ethylenediiminodipropylamines, leurs isomères et dérivés à ponts ainsi que compositions polymériques stabilisées par celle-ci.
HUP9801882A3 (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds and pharmaceutical compositions containing them
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
BR9808348A (pt) Alimento medicinal para diabéticos
CA2183972A1 (fr) Derives de l'oxazolidinone et compositions pharmaceutiques contenant ces derniers
HUP9903336A3 (en) Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds and pharmaceutical compositions containing the same
HUP9802865A3 (en) N-(substituted phenyl)-pyrazole-derivatives, preparation and use thereof, parasiticidal compositions containing these compounds as active ingredients
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
CA2215066A1 (fr) Sulfonylalcanoylamino hydroxyethylamino sulfonamides inhibiteurs de proteases de retrovirus
CA2355618A1 (fr) Suspensions de polyol/huile assurant la liberation prolongee des proteines
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
CA2163837A1 (fr) Hydrates de paclitaxel cristallises
CA2318398A1 (fr) Nouveaux peptides doues d'une action biologique
HUT65127A (en) 1-(3,4-disubstituted phenyl)-tetrazolinone derivatives, herbicidal compositions containing the compounds as active ingredients, processes for producing the active ingredients and compositions and for using them
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
EP1008345A4 (fr) Agents anti-allergiques
ZA978187B (en) Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole compound.
HU9502509D0 (en) Use of 1,4-dihydropyridine-3,5-dicarboxylic-acid-esters as active component of pharmaceutical compositions
WO1997028689A1 (fr) Composition herbicide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

WWE Wipo information: entry into national phase

Ref document number: 09254600

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513454

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA